Genomic Health Announces National Payor Agreement With UnitedHealthcare Insurance Company

REDWOOD CITY, Calif., Jan 10, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company has signed a national payor contract with United HealthCare Insurance Company ("UnitedHealthcare"), an affiliate of UnitedHealth Group (NYSE: UNH), for Oncotype DX, the company's test service that quantifies the likelihood of breast cancer recurrence and predicts the likelihood of chemotherapy benefit for a large portion of early-stage breast cancer patients. UnitedHealthcare is one of the nation's largest private payors. Contracts in place for Oncotype DX have established coverage for over 98 million lives.

The agreement establishes coverage across all of UnitedHealthcare's plans, for women with early-stage breast cancer. Coverage is scheduled to become effective for claims for services performed on or after January 3, 2007.

About Genomic Health

Genomic Health, Inc. is a life science company focused on the development and commercialization of genomic-based clinical laboratory services for cancer that allow physicians and patients to make individualized treatment decisions. In 2004, Genomic Health launched its first test service, Oncotype DX(TM), which has been shown to predict the likelihood of breast cancer recurrence and the likelihood of chemotherapy benefit in a large portion of early-stage breast cancer patients. The company was founded in 2000 and is located in Redwood City, California. For more information, please visit http://www.genomichealth.com .

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the scheduled effective date for coverage. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risk and uncertainties include the risk that conditions for coverage under the contract will not be satisfied and the risks set forth in the Company's filings with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2006. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward- looking statements.

NOTE: The Genomic Health logo, Oncotype, Oncotype DX and Recurrence Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.

SOURCE Genomic Health, Inc. 

Brad Cole of Genomic Health, Inc., +1-650-569-2281, or investors@genomichealth.com;
or Emily Faucette of WeissComm Partners, +1-415-946-1066, or media@genomichealth.com

http://www.genomichealth.com

Copyright (C) 2007 PR Newswire. All rights reserved

News Provided by COMTEX

Contact Information

For Investors:
650.569.2281
investors@genomichealth.com

For Media:
650.569.2215
media@genomichealth.com

  

Email Alerts

To sign-up to receive email alerts for press releases, stock information, new calendar events and/or SEC filings click here.

 

Shareholder Tools

  

DISCLAIMER

The information in the press releases should be considered accurate only as of the date of the document or presentation. We disclaim any obligation to supplement or update the information in these documents or presentations.


Forward-Looking Statements

This website contains forward-looking statements. Any statements contained in this website that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including risks and uncertainties associated with the reimbursement for and adoption of Oncotype DX; commercialization of any future tests; the nature and sources of our revenues; our dependence on collaborative relationships; the regulation of Oncotype DX or any future tests we may develop by the FDA; the attributes of our products; the benefits of personalized medicine and its ability to impact treatment decisions; the outcome and success of clinical trials; the applicability of clinical results to actual outcomes; the company's beliefs regarding the potential benefits that may be obtained from additional tests; and other factors detailed from time to time in Genomic Health's periodic filings with the Securities and Exchange Commission. Genomic Health, Inc. specifically disclaims any obligation to update any forward-looking statements.